Evidence map›Paper›PMID 24747162›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2014

Macromolecular therapeutics.

Jiyuan Yang, Jindřich Kopeček

Abstract readHistorical ArticleReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. PEGylated Oligothioetheramide Prodrugs Activated by Host Serum Proteases.Chembiochem : a European journal of chemical biology · 2021
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Design of smart HPMA copolymer-based nanomedicines.Journal of controlled release : official journal of the Controlled Release Society · 2016
    Review
  14. Article
  15. FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy.Journal of controlled release : official journal of the Controlled Release Society · 2015
    Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jiyuan YangDepartment of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City 84112, USA.
Jindřich KopečekDepartment of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City 84112, USA; Department of Bioengineering, University of Utah, Salt Lake City 84112, USA. Electronic address: jindrich.kopecek@utah.edu.

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
POLYMERIC DRUG DELIVERY SYSTEM FOR CANCER THERAPYR01CA051578 · NCI · UNIVERSITY OF UTAH · PI KOPECEK, JINDRICH H. · 1992 to 2010
$2.8M
Drug-Free Macromolecular TherapeuticsR01GM095606 · NIGMS · UNIVERSITY OF UTAH · PI KOPECEK, JINDRICH H. · 2011 to 2018
$2.3M
BONE TARGETED DELIVERY OF ANABOLIC AGENTSR01GM069847 · NIGMS · UNIVERSITY OF UTAH · PI KOPECEK, JINDRICH H. · 2004 to 2011
$2.3M
DOUBLE-TARGETED MACROMOLECULAR THERAPEUTICS FOR THE TREATMENT OF PROSTATE CANCERR01CA132831 · NCI · UNIVERSITY OF UTAH · PI KOPECEK, JINDRICH H. · 2008 to 2012
$1.5M
HYBRID HYDROGELS SELF-ASSEMBLED FROM GRAFT COPOLYMERSR01EB005288 · NIBIB · UNIVERSITY OF UTAH · PI KOPECEK, JINDRICH H. · 2005 to 2008
$1.2M
Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian CancerR42CA156933 · NCI · THERATARGET · PI KOPECEK, JINDRICH H. · 2014 to 2015
$995k
Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian CancerR41CA156933 · NCI · THERATARGET · PI CHENEY, DARWIN LEROY, KOPECEK, JINDRICH H. · 2011 to 2011
$148k
NCI NIH HHS CA132831NCI NIH HHS CA156933NCI NIH HHS CA51578NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA051578NCI NIH HHS R01 CA132831NCI NIH HHS R41 CA156933NCI NIH HHS R42 CA156933NIBIB NIH HHS EB5288NIBIB NIH HHS R01 EB005288NIGMS NIH HHS GM69847NIGMS NIH HHS GM95606NIGMS NIH HHS R01 GM069847NIGMS NIH HHS R01 GM095606
6 · The paper itself

Abstract

This review covers water-soluble polymer-drug conjugates and macromolecules that possess biological activity without attached low molecular weight drugs. The main design principles of traditional and backbone degradable polymer-drug conjugates as well as the development of a new paradigm in nanomedicines - (low molecular weight) drug-free macromolecular therapeutics are discussed. To address the biological features of cancer, macromolecular therapeutics directed to stem/progenitor cells and the tumor microenvironment are deliberated. Finally, the future perspectives of the field are briefly debated.

Indexed as

Drug CarriersMacromolecular SubstancesPolymersDrug DesignHistory, 20th CenturyHumansNeoplasmsSolubilityStem CellsDrug CarriersMacromolecular SubstancesPolymersCancerDegradable polymeric carriersDrug-free macromolecular therapeuticsMacromolecular therapeuticsN-(2-hydroxypropyl)methacrylamideWater-soluble polymers

Identifiers

PMID24747162
PMCPMC4142088

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.